News Briefs

Blue Cross and Blue Shield of North Carolina is offering certain customers up to a 33% discount on their copays for 90-day orders of maintenance medications. The policy, which became effective July 15, applies to the Blues plan’s fully insured commercial customers. “By reducing how much members pay for their 90-day prescription supply, we hope we can make things a little easier for members in addition to helping them stay home to reduce the spread of COVID-19,” said Rahul Rajkumar, M.D., chief medical officer for the insurer. Read more at https://bit.ly/2CTUSe4.

The average time needed to complete clinical development of new prescription drugs in the United States is lengthening more than the regulatory approval time for new drugs is shortening. That’s according to new research by the Tufts Center for the Study of Drug Development (CSDD), which said the net effect was that the average time to conduct clinical studies and then complete the approval process decreased by 4.8 months from the 2008-2013 time period to 2014-2018. Part of the reason that clinical development time is getting longer is that the number of clinical study participants is growing, according to lead study author Joseph DiMasi, director of economic analysis and research associate professor at Tufts CSDD. Contact Luna Rodriguez at luna.rodriguez@tufts.edu to learn more.

© 2021 MMIT

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/Drug_Benefits_Life_Sciences.jpg
November 23

Will ‘Build Back Better’ Spell Disaster for Pharma Innovation?

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-health-plan-weekly-Wall-Street-Isnt-Sweating-Cignas-Third-Quarter-MLR-Miss.jpg
November 23

Big Three PBMs’ 3Q Results Make Up for Insurer Disappointments

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured_AdobeStock_442155384.jpg
November 23

SCAN Health Opts to Invest in Medication Adherence Tool

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today